525.00p
-0.94%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About 4Basebio
Its shares trade on LSE under the ticker 4BB.L. It has been listed since 17 February 2021. In the fiscal year to 31 December 2025, it reported revenue of £1.7m and a net loss of £16.9m. At that date it held total assets of £29.5m and shareholders' equity of £10.1m.
4basebio Plc is a biotechnology company, which engages in the business of developing advanced therapy medicinal products through synthetic DNA products and non-viral, cell targeting nucleic acid delivery platforms. The company is focused on therapeutic deoxyribonucleic (DNA) for cell and gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. The company is engaged in the manufacturing and supplying of application specific synthetic DNA for research, therapeutic and pharmacological use and develop non-viral vectors for the efficient delivery of payloads. The company has technology in the fields of DNA synthesis and payload delivery, which enables it to manufacture both synthetic DNA constructs and messenger ribonucleic acid (mRNA) and develop vectors for cell and tissue-specific delivery for a range of applications. Its applications include AAV and Lentivirus viral vectors; mRNA vaccines and therapeutics, Genome editing; DNA vaccines, and Hermes non-viral delivery. The company is also focused on exploiting intellectual property in the field of cell and gene therapies and DNA vaccines.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Feb 2021
- Website
- 4basebio.com ↗
Leadership
Pay as last reported
- Ms. Manja BoermanExecutive Chairman of the Board, since 2025
- Dr. Heikki LanckrietChief Executive Officer, Chief Scientific Officer, Executive Director, since 2020£526,200
- Mr. David RothChief Financial Officer, Executive Director, Company Secretary, since 2020£377,800
- Dr. Amy WalkerChief Operating Officer£189,300
- Mr. Gabe LongoriaChief Commercial Officer
- Mr. Hansjoerg PlaggemarsNon-Executive Director£12,800
- Mr. Alexander LinkNon-Executive Independent Director£2,800
- Mr. Alan MalusNon-Executive Independent Director£2,800
- Dr. Michael WassermanNon-Executive Independent Director£1
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- 4Basebio PLC develops synthetic DNA for cell and gene therapies in Cambridge, UK.
- The company manufactures application-specific synthetic DNA for therapeutic use globally.
- 4Basebio PLC holds intellectual property in cell and gene therapy delivery platforms.
Weaknesses
- 4Basebio PLC's business is limited to synthetic DNA and non-viral delivery platforms.
- The company has no manufacturing facilities for viral vectors like AAV or Lentivirus.
- 4Basebio PLC relies on external partners for mRNA vaccine development.
Opportunities
- Expanding DNA vaccine applications in the global health care sector.
- Growing demand for non-viral delivery platforms in gene therapy markets.
- Increasing investment in synthetic DNA manufacturing for research use.
Threats
- Competition from established biotechnology firms in DNA synthesis.
- Regulatory challenges in the Health Care industry for new therapies.
- Potential delays in clinical trials for DNA-based therapies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.